Evidence map›Paper›PMID 34529129›Full record

ArticleJournal of cancer research and clinical oncology2022

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.

Ruth-Miriam Koerber, Stefanie A E Held, Maria Vonnahme, Georg Feldmann, Joerg Wenzel, Ines Gütgemann, Peter Brossart, Annkristin Heine

Open access · hybridAbstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Blastic plasmacytoid dendritic cell neoplasm: Two case reports.World journal of clinical oncology · 2024
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ruth-Miriam KoerberMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0002-8773-8221
Stefanie A E HeldMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Maria VonnahmeMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Georg FeldmannMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0002-3748-2184
Joerg WenzelDepartment of Dermatology and Allergy, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0002-4744-5993
Ines GütgemannDepartment of Pathology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0002-2609-3095
Peter BrossartMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Annkristin HeineMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. Annkristin.Heine@ukbonn.de.ORCID http://orcid.org/0000-0002-5298-9880
University Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an extremely rare disease that originates from dendritic cells and is associated with a poor overall survival (OS). Diagnostic and therapeutic standards are less well-established in comparison to other leukemic conditions and standards of care are lacking. Morphologic and molecular similarities to acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are hard to distinguish. We here report a BPDCN patient with a long, challenging diagnostic period. While bone marrow biopsies initially failed to prove the correct diagnosis, a cutaneous biopsy finally identified a CD45

Indexed as

MutationAgedAntigens, CDBiomarkers, TumorBlast CrisisDendritic CellsDiagnosis, DifferentialDiagnostic ErrorsHematologic NeoplasmsHumansMalePrognosisRecombinant Fusion ProteinsSkin NeoplasmsAntigens, CDBiomarkers, TumorRecombinant Fusion ProteinstagraxofuspAMLBlastic plasmacytoid dendritic cell-neoplasms (BPDCN)MDSMyeloid neoplasiaTagraxofusp

Identifiers

PMID34529129
PMCPMC8881430
OpenAlexW3199797676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.